Takeda Pharma unveils new TOURMALINE-AL1 Phase-3 clinical trial update
Category: #health  By Mateen Dalal  Date: 2019-06-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Takeda Pharma unveils new TOURMALINE-AL1 Phase-3 clinical trial update

· The company announced that the clinical trial failed to fulfil the first of the two preestablished endpoints.

· Citing the result of the analysis, Takeda Pharma has decided to permanently halt the trial.

Takeda Pharmaceutical Company Ltd. (Takeda Pharma), a renowned Japanese pharmaceutical company, has reportedly released a new update on its ongoing Phase-3 TOURMALINE-AL1 clinical trial in individuals suffering from refractory or relapsed systemic light-chain amyloidosis.

Reports cite, the clinical trial failed to fulfil the first of the two preestablished endpoints, wherein an assessment of treatment through a combination of dexamethasone & NINLAROTM (ixazomib).

According to a report by Financial Post, the combination treatment failed to demonstrate any substantial improvement in the patients overall hematologic response as compared to a physician’s preferred standard of care.

The Head of Oncology Therapeutic Area Unit at Takeda, Phil Rowlands, Ph.D., stated that while the company is disappointed with the outcome of the trial, it still aims to maximize its own learnings from the trial and further share any findings with the community with the intention that it would help improve care for individuals that are living with the debilitating disease.

The trial was one of the biggest studies to be ever conducted for systemic light-chain AL amyloidosis, demonstrating the company’s dedication in finding a cure for the rare disease with a patient population that is conventionally difficult to enroll.

Meanwhile, the company remains optimistic regarding NINLARO as an individual entity and would continue to investigate the candidate in patients across the sequence of multiple-myeloma care.

While an Independent Data Monitoring Committee (IDMC) has not raised any concerns about NINLARO’s safety, patients are still encouraged to approach their respective study investigators to address any queries.

According to reports, citing the result of the dexamethasone & NINLARO combination treatment analysis, Takeda Pharma has decided to permanently halt the clinical trial.

Source Credit: https://www.takeda.com/newsroom/newsreleases/2019/takeda-provides-update-on-tourmaline-al1-phase-3-trial/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...